Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK.
Conclusion: Tumor tissue concentration-time curves of CPT-11 and SN-38 can be determined via PBPK modeling. Rate constants of enzymes and transporters can be shown for healthy and tumor bearing individuals. The results will throw light on the effective concentration of active compound at its target tissue at the clinically applied IV dose. PMID: 30760193 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 16, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

From Antimicrobial to Anticancer Peptides: The Transformation of Peptides.
CONCLUSION: These findings may have important clinical implications for cancer treatment, especially in patients with conditions that are not currently treatable by other drugs, or that are resistant to existing cancer drugs. PMID: 30663573 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 23, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents.
CONCLUSION: The promising anti-cancer effects shown by TTs in several preclinical studies may open new opportunities of therapeutic interventions in different tumors. Thus, clinical trials aimed at confirming TTs chemopreventive and tumor-suppressing activity, particularly in combination with standard therapies, are urgently needed. PMID: 30652648 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 18, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.
CONCLUSION: Powerful strategies able to selectively interfere with its expression and function should reveal helpful in the development of new anti-cancer therapies. PMID: 30652649 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 18, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.
CONCLUSION: This review summarizing antigens and approaches to overcome defects of CAR T cell immunotherapy from patents and publications might contribute to broad readership. PMID: 30636615 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 15, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Contemporary Formulations for Drug Delivery of Anticancer Bioactive Compounds.
CONCLUSION: The focus of recent research is not only to clarify the exact mechanisms of action and therapeutic effects, but also to answer the issue of suitable delivery systems that can transport sufficient doses of bioactive compounds to the desired target. PMID: 30636616 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 15, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

New Anti-Cancer Strategies in Testicular Germ Cell Tumors.
CONCLUSION: Finally, the pathogenesis of testicular germ cell tumor needs to be deeply understood so that it will improve data on stem cells, tumorigenesis and disease tumor management by more selective treatment. PMID: 30636617 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 15, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer.
CONCLUSION: Genetic studies highlight the involvement of nicotinic receptors variants in addiction, chronic obstructive pulmonary disease and/or lung cancer. A future important step will be to translate these genetic findings to clinical practice. Interventions able to help smoking cessation in nicotine dependence subjects, under patent, are reported. PMID: 30605063 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 4, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Lentiviral-Mediated Overexpression of MicroRNA-141 Promotes Cell Proliferation and Inhibits Apoptosis in Human Esophageal Squamous Cell Carcinoma.
CONCLUSION: miRNA-141 promotes cell proliferation and inhibits apoptosis in ESCC by down-regulating the expression level of YAP1 and SOX17, indicating that miRNA-141 may be a potential molecular target for the treatment of ESCC. PMID: 30599110 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 3, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Death-Associated Protein Kinase 1 As A Promising Drug Target In Cancer and Alzheimer's Disease.
CONCLUSION: DAPK1 plays a critical role in diverse physiological processes and importantly, its deregulation is implicated in the pathogenesis of either cancer or AD. Therefore, manipulating DAPK1 activity and/or expression may be a promising therapeutic option for cancer or AD. PMID: 30569876 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 22, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

High-throughput Strategy Accelerates the Progress of Marine Anticancer Peptide Drug Development.
Authors: Lyu P, Kwok HF Abstract PMID: 30474536 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 28, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Cucurbitacins as Anticancer Agents: A Patent Review.
CONCLUSION: The significant anticancer effects of natural and semi-synthetic cucurbitacins put them as new drug candidates. Moreover, cucurbitacins have the capability to form conjugates with other anticancer drugs which will synergistically enhance their anticancer effects. The authors believe that in order to get lead compounds, there should be a greater focus on the synthesis of homodimers, heterdimers, and halo derivatives of cucurbitacins. In the opinion of the authors the analysis of the published patents on the cucurbitacins indicates that these compounds can be developed into a regimen to treat a wide spectrum of c...
Source: Recent Patents on Anti-Cancer Drug Discovery - November 21, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents.
CONCLUSION: There is a strong tendency for the development of new nanostructured systems for the release of drugs; particularly, in recent years, the development of nanoparticles has focused on nanodiscs, gold nanoparticles and immunoliposomes. PMID: 30381087 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 2, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A review update of Patent Literature.
CONCLUSION: PD-1/PD-L1 inhibitors show significant anti-cancer responses as stand-alone agents and in combination with other cancer therapies. More efficient experimental studies and clinical trials are necessary to evaluate the host-tumor cells' interactions. Understanding the cancer microenvironment, identifying specific biomarkers and X-ray crystalline structures of PD-1/PD-L1 complexes, including molecular and genomic signature studies are essential to determine the feasibility of PD-1/PD-L1 inhibitors for development into drug-like cancer immunotherapeutics. PMID: 30370857 [PubMed - as supplied by publisher] (Sour...
Source: Recent Patents on Anti-Cancer Drug Discovery - October 30, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Patent Selections.
Authors: PMID: 30306846 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 13, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Acknowledgements to contributors.
ACKNOWLEDGEMENTS TO CONTRIBUTORS. Recent Pat Anticancer Drug Discov. 2018;13(4):479 Authors: PMID: 30306847 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 13, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Recent advances in developing novel anti-cancer drugs targeting tumor hypoxic and acidic microenvironments.
CONCLUSION: Developing more specific agents, and seeking sensitive, applicable and accurate biomarkers may improve the efficacy of drugs targeting hypoxic and acidic microenvironments. PMID: 30173649 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 5, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Journey describing the cytotoxic potential of withanolides: A patent review.
Authors: Hussain H, Csuk R, Green IR, Abbas G, Hussain W Abstract Withanolides are C-28 ergostane steroids known to demonstrate some very interesting therapeutic properties. Numerous withanolides have been isolated from a variety of different plant species and can be employed to treat various types of cancers. Withanolides are indeed capable of demonstrating excellent anticancer, anti-inflammatory, and neuroprotective activities. Additionally, libraries of prepared withaferin A analogs incorporating an acyl, sulphate, amide and aldehyde functionality have demonstrated the most potential response potentials. It is o...
Source: Recent Patents on Anti-Cancer Drug Discovery - August 10, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Semi-synthetic Derivatives of Heliomycin with an Antiproliferative Potency.
CONCLUSION: The patent claims a series of 4-aminomethyl derivatives of heliomycin as well as a pharmaceutical composition based on it. Application of Mannich aminomethylation allowed to diversify the structure of initial antibiotic and to obtain the derivatives with significantly improved water solubility and a potent antiproliferative efficacy. PMID: 30039764 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 25, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
CONCLUSION: In tumor cells, the stabilization of genomic machinery and self-directed death may be achieved via a balanced activation of the AF1 and AF2 domains of ERs by natural estrogen treatment. In contrast, the blockade of either AF1 or AF2 domain by endocrine disruptors leads to toxic symptoms and unforeseeable tumor responses. PMID: 30027855 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 23, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

CS5931, a novel marine polypeptide, inhibits migration and invasion of cancer cells via interacting with enolase 1.
CONCLUSION: Our present study showed that the recombinant CS5931 could inhibit tumor invasion and metastasis via interacting with enolase 1, suggesting that the new marine polypeptide CS5931 possesses the potential to be developed as a novel anticancer agent. PMID: 29956637 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 1, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Targeting Metabolism to Counteract Tumor Angiogenesis: A Review of Patent Literature.
Authors: Petrillo S, Tolosano E, Munaron L, Genova T Abstract Massive vessel recruitment is required to sustain rapid tumor growth by delivering oxygen and nutrients. Current strategies to counteract angiogenesis are mostly aimed at reducing tumor vessel density. However, many of these drugs have been shown to trigger hypoxia, thus exacerbating tumor aggressiveness. Promising results come from a completely different approach based on the "normalization" of the endothelial layer and the consequent improvement of the vascular function. Since endothelial metabolism has proved essential in the regulation of t...
Source: Recent Patents on Anti-Cancer Drug Discovery - May 31, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Patent Selections.
Authors: PMID: 29788867 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 25, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Evolving strategies for the treatment of T-cell lymphoma: a systematic review and recent patents.
CONCLUSION: Therapeutic strategies based on better molecular characterization of various histological types are certain to be used in the future. PMID: 29769011 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 18, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Synthesis, in-silico and in-- vitro cytostatic activity of new lipophilic derivatives of hydroxyurea.
CONCLUSION: Compound 7 with the suitable volume, log p and shape is the more or most active ligand against both cell lines. It is concluded or suggested that the size, shape and hydrophobic character of substituents strongly affect the pharmacodynamics and pharmacokinetic of these type of ligands. PMID: 29769012 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 18, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Recent Progress of Marine Polypeptides as Anticancer Agents Marine Polypeptides as Anticancer Agents.
CONCLUSION: Marine peptides possess chemical diversity and displays potent anticancer activity via targeting different signal pathways. Some of the marine peptides are promising to be developed as novel anticancer agents. PMID: 29708076 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 2, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Emerging Drugs for the Treatment of Breast Cancer Brain Metastasis: A Review of Patent Literature.
CONCLUSION: In this study we found 35 drug targets for metastasis to the brain in breast cancer, with 60% of them including only one patent, which establishes that this area of research is very recent, and that these targets have recently been linked to metastasis to the brain. On the other hand, 19 drug targets, among them VEGF, VEGFR2, CXCL12, and CXCR4, have been addressed for the first time until 6 years ago, confirming that the development of drugs for brain metastasis in breast cancer is an incipient area, but with interesting potential. Interestingly, the stage of inside the brain, was the stage with the lowest amou...
Source: Recent Patents on Anti-Cancer Drug Discovery - May 2, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Low dose of acacetin promotes breast cancer MCF-7 cells proliferation through the activation of ERK/ PI3K /AKT signaling pathway.
Conclusion Low dose of acacetin from 10^-3 μM to 1 μM promoted the proliferation of MCF-7 cells through the ERK/PI3K/AKT pathway and its downstream cyclin signaling, and this pathway is mainly mediated by the expression of ERα. PMID: 29676234 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 22, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Anti-Cancer Effect of ɑ-Solanine Mainly by Down-Regulating S100P Expression in Colorectal Cancer Cells.
CONCLUSION: These findings suggest that ɑ-solanine is a potential agent for the treatment of CRC, and the anti-tumor effect of ɑ-solanine in the CRC cells may be mediated at least partly by the downregulation of S100P. PMID: 29600769 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 1, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells may be induced by Interactions between Receptor Tyrosine Kinases and ER α-66.
CONCLUSION: Altogether, it seems that tumor cells express a stemness phenotype which tends to override anti-hormonal adjuvant therapies. Thus, targeting pathways that can lead to stemness can be an effective approach in reversing resistance. Since RTKs are overactivated and overexpressed in such cells, specialized targeted therapies suppressing RTKs would be a novel and effective way in restoring tamoxifen sensitivity in resistant breast cancer tumor cells. PMID: 29512469 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 9, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

PARP Inhibitors in Ovarian Cancer.
CONCLUSION: PARPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease. Further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC. PMID: 29512470 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 9, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients.
CONCLUSION: PTX TC>0.05 is a key pharmacokinetic parameter of PTX which should be monitored to optimize individual treatment in patients with solid tumors. PMID: 29512471 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 9, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Oral Submucous Fibrosis as an Overhealing Wound: Implications in Malignant Transformation.
CONCLUSION: Considering, Oral submucous fibrosis as an overhealing wound explains both pathogenesis and malignant transformation. Certainly, abnormalities in coagulation and fibrinolytic system are a common denominator in the profibrotic milieu and associated malignancy. PMID: 29485009 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 1, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

The Application of lncRNAs in Cancer Treatment and Diagnosis.
CONCLUSION: Current knowledge of lncRNAs presents prosperous prospects in cancer. However, functions of lncRNAs are still far from fully understood. Therefore, further study is need to advance imminent applications of these findings to the clinic. PMID: 29485010 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 1, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied.
CONCLUSION: On the base of the above mentioned considerations, it is necessary to prove the effectiveness of lenvatinib in the context of associated moderate to severe toxicities requiring frequent dose reduction and delays, and for this reason many interesting patents have been recently applied. PMID: 29468981 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 24, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation.
CONCLUSION: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases. PMID: 29468982 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 24, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Synthesis and DFT study on Hantzsch reaction to produce asymmetrical compounds of 1,4-dihydropyridine derivatives for P-glycoprotein inhibition as anticancer agent.
CONCLUSION: In this study, selected reactants by DFT calculation have increased yield of reaction from 36% to 74% without any catalyst. Diversity of products is noticeable topic. Racemic asymmetric compounds with R and S enantiomers have potential for enantiomeric separation. Each of these enantiomers could have different physiological effect. PMID: 29468983 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 24, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies.
Conclusion: A greater understanding of the molecular events associated with antioxidants will enhance the development of treatment and could result in better strategies for the chemoprevention of prostate cancer. Recent patents also suggest that anti-oxidant compounds can be effective for the prevention and the treatment of prostate cancer. PMID: 29446748 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 17, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Αnaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
CONCLUSION: ALK targeting holds promise as novel therapeutic approach in GBM, especially in combination schemes allowing multi-target therapy. Such schemes may incorporate detection-guided therapy and utilize next generation inhibitory compounds with improved central nervous system penetration. Moreover, identification of ALK-mediated molecular pathway(s) related to GBM carcinogenesis/pathology and putative therapy resistance is of high priority and warrants further exploitation. PMID: 29336268 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 18, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Reduced Lipocalin 2 Expression Contributes to Vincristine Resistance in Human Colon Cancer Cellsance in Human Colon Cancer Cells.
CONCLUSION: Overall, these results demonstrate that LCN2 plays an important role in VCR resistance and is a potential therapeutic target for this disease. PMID: 29268690 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 23, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Advances In the Discovery of Anthraquinone-Based Anticancer Agents.
CONCLUSION: A number of newly discovered natural products, the perspective directions for chemical modifications to optimize the anticancer properties, and novel intracellular targets demonstrate that anthracene-9,10-diones deserve further in-depth investigation as an important source of drug candidates. PMID: 29210664 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 8, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

PARP inhibitors in epithelial ovarian cancer.
Conclusion PARP inhibitors have emerged as an exciting new drug class in the treatment of epithelial ovarian cancer. Ongoing studies are aimed at improving our ability to identify ideal candidates for PARP inhibitor therapy, as well as to identify and target mechanisms of drug resistance, and novel combinatorial approaches. PMID: 29205122 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 6, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Brain Cancer: Implication to disease, therapeutic strategies and tumor targeted drug delivery approaches.
CONCLUSION: Novel strategies focused towards targeting drug substances specifically to brain tumor site would increase the therapeutic efficiency and reduce the toxicity of chemotherapeutics. PMID: 29189177 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 3, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins.
CONCLUSION: In this review article, we provide an overview of the current preclinical and clinical status of statins as antitumor agents. In addition, we evaluated various patents that describe the role of mevalonate pathway inhibitors and methods to determine if cancer cells are sensitive to statins treatment. PMID: 29189178 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 3, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
CONCLUSION: The review will describe a variety of specific inhibitor classes and conclude on recent and future therapeutic perspectives for this target. PMID: 29119937 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 11, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Adenosine receptor ligands on cancer therapy: A review of Patent Literature.
CONCLUSION: The promising anticancer effects mediated by adenosine receptor ligands put them in the forefront as new drug candidates. The present compilation can be worthy to medicinal chemists, pharmacologists, biochemists and other researchers focusing on the putative anticancer activity of adenosine receptor ligands. PMID: 29119938 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 11, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Conclusion It is highly relevant to deepen the study of the nucleic acid-sensing mechanisms to develop new pharmacological approaches to engage these pathways within the tumour microenvironment. Indeed, further clarification will be functional to develop advanced anticancer strategies or to design new vaccines formulation. PMID: 29086701 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 2, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer.
CONCLUSIONS: In females with breast cancer, a possible metastasis in the stomach should be taken into account. Maspin and VSIG1 are not involved in breast cancer histogenesis. The Wnt/β-catenin signaling is not involved in the lobular carcinoma progression. The CD44/HER2 positivity in ductal carcinoma cells might indicate high risk of distant metastasis and low response to chemotherapy. PMID: 29090670 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 2, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents.
CONCLUSION: The vigorous effort to discover and develop agents to specifically inhibit NLRP3 inflammasome activation, may pave the way to therapeutic intervention targeting inflammasome-regulated pathways that are involved in the pathogenesis of various forms of cancer. PMID: 29076433 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 29, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Molecular modelling of berberine derivatives as inhibitors of human smoothened receptor and hedgehog signalling pathway using a newly developed algorithm on anti-cancer drugs.
CONCLUSION: This study predicted the role of berberine as an inhibitor of Smo receptor, suggesting its effectiveness in hedgehog signalling during cancer treatment. PMID: 28969581 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 5, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research